Predictive role of CD3, CD4, CD8, CD20 to neoadjuvant chemotherapy response in triple negative breast cancer patients

سال انتشار: 1394
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 422

نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد

این مقاله در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

ICBCMED12_150

تاریخ نمایه سازی: 2 تیر 1397

چکیده مقاله:

Introduction & Aim: Tumor-infiltrating lymphocytes in breast cancer have been proposed as a new marker in the diagnosis of the patient s immune response. This study was aimed to determine predictive in response to neoadjuvant chemotherapy in patients with triple negative breast cancer. Methods: A cross-sectional study was done in 40 patients with breast cancer was referred to Cancer Institute, Imam Khomeini Hospital, Tehran, in April,2014 to April, 2016.T lymphocyte subtypes included CD3, CD4, CD8, CD20 and androgen receptor were investigated by Immunohistochemistry analysis pre and post-surgery. Pathologic complete response after surgery was determine Results: 22 patients were in Stage II and 18 patients were in Stage III. 13 patients had low levels of TILs and 27 patients had high levels of TILs. Six patients were positive in androgen receptor (AR).15 cases had a complete pathologic response. In the CD8-negative group, the most patients with low-levels of TILs had no complete pathological response but the most patients with high-levels of TILs had complete pathological response. In patients with CD20 positive had no impact on the patient s pathological response in terms ofthe TILs level, although, in the Absence and Mild level, the most pathological responses (80%) were negative and in the Moderate level, all pathological responses were positive. Conclusion: The findings of the study showed that Tumor-infiltrating lymphocytes can predict response to chemotherapy in patients with triple negative breast cancer after neoadjuvant therapy. Also, age, CD4 and CD8 indicators had predictive value to complete pathologic response based on TILs levels

نویسندگان

Nafiseh Ansarinejad

Department of Hematology-Oncology, Iran University of Medical Sciences, Tehran, Iran.

Farshid Fardad

Department of Hematology-Oncology, Iran University of Medical Sciences, Tehran, Iran.

Bahareh Abbasi

Department of Medical Genetic, Medical Biotechnology Ins., National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran

Tayeb Ramim

Cancer Pharmacogenetics Research Group (CPGRG), Iran University of Medical Sciences, Tehran, Iran